---
title: Prevent tremor relapse after thalamotomy
nct_id: NCT07284719
phase: NA
status: RECRUITING
sponsor: Aarhus University Hospital
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07284719"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07284719"
last_fetched: "2026-05-10T14:06:20.816Z"
source: "Parkinson's Pathways (curated)"
---
# Prevent tremor relapse after thalamotomy

**Goal (in five words):** Prevent tremor relapse after thalamotomy

**Official Title:** Predictors and Mechanisms of Tremor Relapse After MR-Guided Focused Ultrasound Thalamotomy in Parkinson's Disease

**Trial ID:** [NCT07284719](https://clinicaltrials.gov/study/NCT07284719)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Aarhus University Hospital
- **Target Enrollment:** 20 participants
- **Start Date:** 2025-12-01
- **Completion Date:** 2028-12
- **Conditions:** Parkinson s Disease, Tremor
- **Interventions:** MR-guided focused ultrasound thalamotomy
- **Intervention Types:** PROCEDURE

## Summary For Families

The goal is to find why tremor sometimes comes back after MR-guided focused ultrasound thalamotomy, by identifying clinical and brain-imaging predictors and underlying mechanisms of relapse. The approach uses MRI to aim focused ultrasound beams through the skull to heat and ablate a very small spot in the thalamus that drives tremor, interrupting the tremor circuit without open brain surgery, and then follows patients over time to see what changes predict return of tremor. This procedure does not change how levodopa replaces dopamine for other Parkinson symptoms, though it may reduce tremor and the need for tremor-specific medications in some people. The trial is enrolling people aged 50 to 80 with idiopathic Parkinsons whose tremor is not manageable with optimal medication, with Hoehn and Yahr stage under 3, adequate skull density for ultrasound, ability to have MRI and lie flat for a few hours, and without dementia, major psychiatric or other MRI contraindications.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Established diagnosis of idiopathic Parkinson's disease
* Tremor not manageable with optimal medication
* Clinical Indication for MRgFUSth
* Able to understand study requirements and provide consent
* HOEHN and YAHR \<3

Exclusion Criteria:

* Dementia or severe cognitive impairment
* The presence of another significant neurological/psychiatric disorder or significant disease
* Severe psychopathology, not medically managed
* Poor balance and gait function based on neurological examination
* Epilepsy
* Active drug abuse
* History of stroke or structural lesions on MRI that could interfere with image analysis.
* Contraindications for MRI
* Cardiac pacemaker
* Pregnancy or breast-feeding
* Claustrophobia
* Patients unable to lie on the back for 2-4 hours in the MR-scanner-setting
* Patients who do not want information about findings of unknown disease during the trial
* SDR (Skull density rate) lower than 0.35
```

## Locations (1)

- Aarhus University Hospital, Aarhus, Denmark _(56.1567, 10.2108)_
  - Morten L Nørholt, MD — (CONTACT) — +78450000 — moln@clin.au.dk
  - (CONTACT) — +78450000 — au454377@uni.au.dk
  - Morten L Norholt, MD — (SUB_INVESTIGATOR)
  - Andreas N Glud, Associate Professor — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Andreas N Glud, Associate Professor — (CONTACT) — +4523882213 — andglu@rm.dk

---

*Canonical: https://parkinsonspathways.com/trial/NCT07284719*  
*HTML version: https://parkinsonspathways.com/trial/NCT07284719*  
*Source data: https://clinicaltrials.gov/study/NCT07284719*